A Pharmaceuticals and Healthcare (Biopharmaceuticals and Biotherapeutics) and Food and Beverage-Processing (Processed Food Products) entity from India is looking to raise strategic funding.

BUSINESS BRIEF

The company has grown organically and through joint ventures and acquisitions, leveraging the resources of its former parent company. It benefited from the previous rounds of capital raising done at the group level, where both strategic and financial investors actively committed to support the growth of the group. The co. has developed biosimilar versions of molecules, in the areas of oncology, cardiovascular, anemia, autoimmune disorders and, for which the patent protection of the originator drug is either not valid for India and certain developing markets or is expected to expire worldwide. With the outbreak of the COVID-19 pandemic, effective treatments are urgently needed which integrate the management of COVID19 induced inflammation and coagulopathies. Our unique therapeutic proposal is to repurpose our proprietary combination of our clinically validated biosimilars for effective COVID19 management that act against overt inflammation, coagulation leading to microthrombosis and maintenance of normal levels of blood oxygen saturation by supporting effective RBC production and restoration of hypoxemic conditions through combinatorial dosage of four products to address the dynamic COVID19 drug market opportunity for further development scale up and completion of Phase I and Phase II clinical trials.

Proposal

Capital Requirement USD 10 to 15 Mn
Justification: Research and Development with a portfolio of diverse product pipeline Unique and cost-effective therapeutic product portfolio for COVID19 management with a focus on market opportunities with significant need and a high commercial potential. Access to world-class and industry leading resources through global partnerships and collaboration efforts. Experienced management team and scientific advisory board
Funding Route

Private Equity, Strategic Investor

Extent Of Dilution

Upto 26 %

Share Holding Pattern

Promoter Group 100%

Non-Promoter Share Holder 0%

Reason For Raising Capital

Organic Growth,

Business Operating Information

Industry

Pharmaceuticals and Healthcare

Sub-Industry

Biopharmaceuticals and Biotherapeutics

Division

Division`s Market Share

Division`s Growth rate in 3 years

Division`s Key Partnership`s

Not Disclosed

Division`s Buyers/Customers

Division`s Plant Location

Division`s Products/Services

Market Share %

Not Disclosed

Growth rate in 3 years

Not Disclosed

Key Partnerships

Not Disclosed

Industry

Food and Beverage-Processing

Sub-Industry

Processed Food Products

Division

Division`s Market Share

Division`s Growth rate in 3 years

Not Disclosed

Division`s Key Partnership`s

Not Disclosed

Division`s Buyers/Customers

Division`s Plant Location

Division`s Products/Services

Market Share %

Not Disclosed

Growth rate in 3 years

Not Disclosed

Key Partnerships

Not Disclosed

Financial Information

2017 (in USD) 2018 (in USD) 2019 (in USD) 2020 (in USD)
Sales 2.2 Mn 3.7 Mn 4.5 Mn 4 Mn
EBDITA
PAT N.D N.D N.D N.D
TANGIBLE NET WORTH N.D N.D N.D N.D
LONG TERM DEBT N.D N.D N.D N.D
TOTAL DEBT N.D N.D N.D N.D

Business Document

Other

Business Model

Information memo

CONTACT BUSINESS

If you are interested in connecting with business please send an Expression of Interest.

SHARE VIA
CONTACT DETAILS